Le Lézard
Classified in: Health, Business
Subject: TNM

Greenberg Traurig Represents ONO Pharmaceutical Co. in $2.4B Acquisition of Deciphera Pharmaceuticals


Global law firm Greenberg Traurig, LLP represented Japan-based global specialty pharmaceutical company ONO Pharmaceutical Co. in its acquisition of Waltham, Massachusetts-based Deciphera Pharmaceuticals for $25.60 per share in cash, for a total equity value of $2.4 billion.

WASHINGTON, April 30, 2024 /PRNewswire-PRWeb/ -- Global law firm Greenberg Traurig, LLP represented Japan-based global specialty pharmaceutical company ONO Pharmaceutical Co. in its acquisition of Waltham, Massachusetts-based Deciphera Pharmaceuticals for $25.60 per share in cash, for a total equity value of $2.4 billion.

The deal is expected to close in the third quarter of 2024, subject to customary closing conditions and regulatory approvals.

ONO said that as a wholly owned subsidiary Deciphera's research and development capabilities in the cancer field and commercial capabilities in the United States and Europe will reinforce ONO's pipeline and accelerate global development.

"It has been an honor to work with ONO, a 300-year-old company with a strong innovative portfolio, and guide them through this transaction that will help grow their capabilities to help those diagnosed with cancer and other diseases around the globe," said Chia-Feng Lu, a Washington, D.C., based Life Sciences and Medical Technology shareholder who co-led the deal. "The scope of this transaction, which involved multiple jurisdictions and a broad array of highly complex corporate and regulatory work, demonstrates the strength of Greenberg Traurig's global platform in life sciences. I look forward to continuing our work with ONO in the years to come."

You can learn more in ONO's press release here.

The Greenberg Traurig team was led by Lu and New York Corporate Shareholder Michael D. Helsel.

About Greenberg Traurig: Greenberg Traurig, LLP has more than 2750 attorneys in 47 locations in the United States, Europe and the Middle East, Latin America, and Asia. The firm is a 2022 BTI "Highly Recommended Law Firm" for superior client service and is consistently among the top firms on the Am Law Global 100 and NLJ 500. Greenberg Traurig is Mansfield Rule 6.0 Certified Plus by The Diversity Lab. The firm is recognized for powering its U.S. offices with 100% renewable energy as certified by the Center for Resource Solutions Green-e® Energy program and is a member of the U.S. EPA's Green Power Partnership Program. The firm is known for its philanthropic giving, innovation, diversity, and pro bono. Web: http://www.gtlaw.com.

Twitter

SOURCE Greenberg Traurig


These press releases may also interest you

at 14:05
IGC Pharma, Inc ("IGC" or the "Company"), today announced that the Company will be participating in the BIO International Convention taking place at the San Diego Convention Center from June 3-6, 2024. During the conference, members of the IGC...

at 14:00
The Weinbach Group, a leading healthcare advertising agency, announced CitiMed, a multispecialty, fully integrated healthcare practice with five locations throughout Miami-Dade and Broward Counties, engaged the firm to handle marketing and...

at 13:50
Genesis + HOCL, the leading innovator in HOCL atomizing technology, is set to be featured on 'Great Day Washington' on WUSA, Channel 9 in Washington, DC. The segment will air today, Tuesday, May 21, at 3:00 pm EDT, coinciding with Clean Air Month...

at 13:48
Action on Smoking and Health (ASH) and their partners at Unfairtobacco released a joint report in advance of World No Tobacco Day on May 31st. The report, Protecting Children from the Tobacco Industry, highlights the myriad ways the tobacco industry...

at 13:35
Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, today announced the completion of enrollment in its randomized, multicenter, double-blind, placebo-controlled Phase 2b clinical trial of...

at 13:35
Asymchem Laboratories (Tianjin) Co., Ltd. (Stock Code 002821.SZ/6821.HK) announced today that it will operate the former Pfizer U.K. small molecule API pilot plant and part of the development laboratories through a new lease agreement between...



News published on and distributed by: